Thus, antibody-mediated blockade of CTLA-4 may ultimately prove useful, either alone or in combination with other immune-based manipulations, to improve the effectiveness of ESCC treatment. This evidence concerns the gene CTLA4 and esophageal squamous cell carcinoma.